CD274 and non-small cell lung carcinoma: Checkpoint immunotherapy has been approved as first-line therapy for patients with Non-small cell lung cancer (NSCLC) expressing programmed cell death-ligand 1 (PD-L1) (tumor proportion score (TPS) ≥ 1%) [5, 6].